Vassiliadis E et al. demonstrated increased circulating levels of citrullinated and matrix metalloproteinases (MMP)-degraded vimentin (VICM) in a mouse model of hepatic fibrosis and in patients with early hepatic fibrosis associated with HCV and nonalcoholic fatty liver disease [27]. Here, VIM is linked to metabolic dysfunction-associated steatotic liver disease.